Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The most effective treatment of well-differentiated endometrial carcinoma is surgery. The aim of this study is the evaluation of megestrol acetate on young patients with well-differentiated endometrial cancer who wish to preserve their fertility, with regard to the receptors.
16 patients were treated initially with 160 mg/d of megestrol acetate and continued with 320 mg/d for non-responsive cases. All patients followed with FD&C and hysteroscopy. The responsive patients were referred to IVF group.
Response rate to hormonal therapy was 10/16 (62.5%). The mean time of responding was 7.5 months. Other six (37.5%) patients underwent total abdominal hysterectomy (TAH).
Of 10 patients who responded to hormonal therapy, one exited of the study because of her husband’s infertility. Two patients are under IVF. Three patients did not get pregnant and four patients became pregnant and finally underwent TAH.
All patients had progesterone receptors. Only one patient lacked estrogen receptors; who also responded to treatment.
Progestins treatment of these patients who want to have child may be useful, but close long-term follow-up is necessary. The evaluation of estrogen and progesterone receptors assay may be useful in predicting response to the treatment.
- Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC (2008) Current issues in the management of endometrial cancer. Mayo Clin Proc 83(1):97–112 (review) CrossRef
- Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95:133–138 CrossRef
- Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial. Cancer risk Br J Cancer 57(2):205–212
- Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, Demichele A, Garcia-Closas M, Goodman MT, Haiman CA, Hankinson SE, Henderson BE, Horn-Ross PL, Lacey JV Jr, Le Marchand L, Levine DA, Liang X, Lissowska J, Lurie G, McGrath M, Narod SA, Rebbeck TR, Ursin G, Weiss NS, Xiang YB, Yang HP, Zheng W, Olson SH (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 18(1):242–247 CrossRef
- Frumovitz M, Gershenson DM (2006) Fertility-sparing therapy for young women with endometrial cancer. Expert Rev Anticancer Ther 6:27–32 CrossRef
- Boing C, Kimmig R (2006) Fertility-preserving treatment in young women with endometrial cancer. Gynakol Geburtshilfliche Rundsch 46:25–33 CrossRef
- Podczaski E, Mortel R (2001) Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol 15:469–489 CrossRef
- Yang YC, Wu CC, Chen CP, Chang CL, Wang KL (2005) Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 99:287–293 CrossRef
- Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S (2009) Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 19(2):249–252 CrossRef
- Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79:320–327 CrossRef
- Yahata T, Fujita K, Aoki Y, Tanaka K (2006) Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21(4):1070–1075. Epub 2005 Dec 16. PubMed PMID: 16361282
- Zivanovic O, Carter J, Kauff ND, Barakat RR (2009) A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 115(3):504–509. (Epub 2009 Sep 15)
- Lai CH, Huang HJ (2006) The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 18(1):29–34
- Markman M (2005) Hormonal therapy of endometrial cancer. Eur J Cancer 41(5):673–675 CrossRef
- Ota T, Yoshida M, Kimura M, Kinoshita K (2005) Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 15:657–662 CrossRef
- Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T (2005) Outcome of fertility-preserving treatment in young women with endometrial carcinomas. Bjog 112:317–320 CrossRef
- Mousavi AS, Behtash N, Karimi Zarchi M, Modarres Gilani M, Ghaemmaghami F (2007) Fertility preservation in young women with endometrial carcinoma; report of three cases. Tehran Univ Med J 65(2):82–87
- Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate
Archives of Gynecology and Obstetrics
Volume 285, Issue 3 , pp 791-795
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Hormonal therapy
- Progesterone receptor
- Well-differentiated endometrial carcinoma
- Industry Sectors
- Author Affiliations
- 1. Department of Obstetrics and Gynecology, Women Hospital (Mirza Koochackhan), Tehran University of Medical Sciences, Tehran, Iran
- 2. Department of Gynecology Oncology, Women Hospital (Mirza Koochackhan), Tehran University of Medical Sciences, Tehran, Iran
- 3. Preventive and Community Medicine Specialist, Brain and Spinal Injury Repair Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran